

# Eric Laille

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6139140/publications.pdf>

Version: 2024-02-01

23  
papers

1,168  
citations

623734

14  
h-index

642732

23  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 2521-2527.	1.6	232
2	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. <i>Blood</i> , 2008, 112, 981-989.	1.4	229
3	CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2017-2024.	2.0	122
4	Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 1940-1947.	1.6	116
5	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. <i>Leukemia</i> , 2016, 30, 889-896.	7.2	94
6	Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies. <i>American Journal of Hematology</i> , 2018, 93, 1199-1206.	4.1	54
7	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies. <i>PLoS ONE</i> , 2015, 10, e0135520.	2.5	54
8	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1426-1436.	1.6	49
9	Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study. <i>International Journal of Hematology</i> , 2017, 106, 655-665.	1.6	33
10	Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 630-639.	2.0	31
11	Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial. <i>Blood</i> , 2023, 141, 156-167.	1.4	27
12	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 4072-4080.	7.0	25
13	Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles ( <i>Caretta caretta</i> ). <i>American Journal of Veterinary Research</i> , 2003, 64, 304-309.	0.6	21
14	Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 7-14.	2.8	15
15	A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment. <i>Pharmacotherapy</i> , 2014, 34, 440-451.	2.6	14
16	In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 995-1000.	2.3	10
17	Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1378-1385.	2.0	9
18	Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single-arm, open-label phase 2 study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 270-278.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 621-626.	2.3	9
20	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , 2020, 26, 5329-5337.	7.0	6
21	Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e430-e439.	1.1	4
22	Pharmacokinetics and safety of apremilast (CC-10004) in subjects with hepatic impairment. <i>International Journal of Medical Engineering and Informatics</i> , 2014, 6, 100.	0.3	3
23	Azacitidine is removed effectively by hemodialysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 743-745.	1.3	2